Canaccord analyst William Plovanic lowered the firm’s price target on Staar Surgical to $31 from $33 and keeps a Hold rating on the shares. The firm updated its model following the release of its preliminary Q4 and 2023 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Fly Insider: Athira Pharma, Microstrategy among week’s notable insider trades
- Staar Surgical sees FY24 revenue $335M -$340M, consensus $366.8M
- Staar Surgical sees FY23 revenue $322.5M , consensus $320.5M
- Staar Surgical sees Q4 revenue $76.5M, consensus $74.23M
- Insider Trading: Staar Surgical Stock (NASDAQ:STAA) Gained After $6.5M Insider Purchase
